Who are the top shareholders of the Advanced Enzyme?

The top shareholders of Advanced Enzyme include promoters holding the majority of shares, with Vasant Rathi having the largest stake at 33.18%. Additionally, mutual funds own 5.36%, foreign institutional investors hold 11.9%, and individual investors collectively own 16.68%.

The top shareholders of Advanced Enzyme include the promoters, who hold the majority of the shares. Notably, Vasant Rathi is the promoter with the highest holding at 33.18%. Additionally, the company has 9 mutual fund schemes holding a combined 5.36% and 70 foreign institutional investors (FIIs) holding 11.9%. Individual investors collectively hold 16.68% of the shares. The highest public shareholder is Orbimed Asia III Mauritius Fvci Limited, which holds 0%. There are no pledged promoter holdings reported.

how big is Advanced Enzyme?

As of Jun 06, Advanced Enzyme Technologies Ltd has a market capitalization of 3,394.47 Cr, with recent net sales of 636.91 Cr and net profit of 131.11 Cr over the last four quarters. Shareholder's funds are 1,324.13 Cr, and total assets are valued at 1,521.18 Cr as of Mar'24.

Market Cap: As of Jun 06, Advanced Enzyme Technologies Ltd has a market capitalization of 3,394.47 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 636.91 Cr, and the sum of Net Profit is 131.11 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the reporting period of Mar'24. The Shareholder's Funds amount to 1,324.13 Cr, and the Total Assets are valued at 1,521.18 Cr.

When is the next results date for Advanced Enzyme?

No Upcoming Board Meetings

Has Advanced Enzyme declared dividend?

Yes, Advanced Enzyme Technologies Ltd has declared a dividend of 200%, amounting to ₹4 per share, with an ex-date of May 16, 2025. The dividend yield is 1.68%, and while recent returns have been volatile, the total return over the past five years is 104.53%.

Advanced Enzyme Technologies Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4<BR>- Ex-date: May 16, 2025<BR><BR>Dividend Yield: 1.68%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -19.63%, the dividend return was 1.02%, resulting in a total return of -18.61%.<BR><BR>Over the past year, the price return was -15.92%, with a dividend return of 1.41%, leading to a total return of -14.51%.<BR><BR>In the 2-year period, the price return was 8.5%, the dividend return was 3.69%, culminating in a total return of 12.19%.<BR><BR>For the 3-year period, the price return stood at 1.81%, the dividend return was 5.62%, resulting in a total return of 7.43%.<BR><BR>In the last 4 years, the price return was -26.95%, while the dividend return was 3.89%, leading to a total return of -23.06%.<BR><BR>Finally, over the past 5 years, the price return was 94.86%, the dividend return was 9.67%, resulting in a total return of 104.53%.<BR><BR>Overall, Advanced Enzyme Technologies Ltd has declared a significant dividend, and while recent returns have shown volatility, the long-term performance over five years indicates a strong total return driven by both price appreciation and dividends.

Is Advanced Enzyme overvalued or undervalued?

As of July 30, 2020, Advanced Enzyme is considered very expensive and overvalued with a PE ratio of 25.89, despite outperforming the Sensex in the short term, while its year-to-date performance is down by 10.37%.

As of 30 July 2020, the valuation grade for Advanced Enzyme moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE ratio of 25.89, an EV to EBITDA of 14.64, and a Price to Book Value of 2.39, all of which suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Advanced Enzyme's PE ratio is notably lower than Solar Industries at 123.77 and Gujarat Fluoroch at 73.59, both of which are also classified as very expensive. However, it is significantly higher than Godrej Industries, which is rated attractive with a PE of 46.63. The recent stock performance shows a 1-month return of 11.21%, outperforming the Sensex's 3.87% return, but the year-to-date performance is down by 10.37%, contrasting with the Sensex's gain of 5.62%. This mixed performance further supports the conclusion of overvaluation.

Who are the peers of the Advanced Enzyme?

Peers of Advanced Enzyme include Hikal, RPG LifeScience, Dishman Carbogen, Guj. Themis Bio., Orchid Pharma, Gufic BioScience, Morepen Labs., Indoco Remedies, and Senores Pharma. RPG LifeScience shows the highest 1-year return at 44.57%, while Advanced Enzyme's return is -12.83%.

Peers: The peers of Advanced Enzyme are Hikal, RPG LifeScience., Dishman Carbogen, Guj. Themis Bio., Orchid Pharma, Gufic BioScience, Morepen Labs., Indoco Remedies, and Senores Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience., while Good management risk is found at Hikal, Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme. Average management risk is present at Dishman Carbogen, Morepen Labs., and Indoco Remedies, while Below Average management risk is noted at Orchid Pharma and Senores Pharma. All peers exhibit Below Average growth, except for Morepen Labs., which has Good growth, and Senores Pharma., which has Excellent growth. Capital Structure ratings show Excellent at RPG LifeScience., Guj. Themis Bio., Gufic BioScience, and Morepen Labs., Average at Hikal and Indoco Remedies, and Below Average at Dishman Carbogen, Orchid Pharma, and Senores Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is RPG LifeScience. at 44.57%, while Orchid Pharma has the lowest at -34.27%. Advanced Enzyme's 1-year return is -12.83%, which is higher than Orchid Pharma's but lower than RPG LifeScience.'s. Additionally, Orchid Pharma and Gufic BioScience have negative six-month returns.

Who are in the management team of Advanced Enzyme?

As of March 2023, the management team of Advanced Enzyme includes Mukund Madhusudan Kabra (Whole-time Director), Vasant Rathi (Chairman), and several independent and non-executive directors, totaling 12 key members who guide the company's governance and strategy.

As of March 2023, the management team of Advanced Enzyme includes the following individuals:<BR><BR>1. Mukund Madhusudan Kabra - Whole-time Director<BR>2. Kedar Jagdish Desai - Independent Director<BR>3. Vasant Rathi - Chairman (Non-Executive)<BR>4. Pramod Kasat - Independent Director<BR>5. Sanjay Basantani - Company Secretary & Compliance Officer<BR>6. Rajesh Kumar Sharma - Independent Director<BR>7. Rasika Rathi - Non-Executive & Non-Independent Director<BR>8. Vindokumar Hiralal Jajoo - Independent Director<BR>9. Sunny Sharma - Non-Executive & Non-Independent Director<BR>10. Rajshree Patel - Independent Director<BR>11. Nitin Jagannath Deshmukh - Independent Director<BR>12. Vandana Tilak - Independent Director<BR><BR>This diverse team includes a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

What does Advanced Enzyme do?

Advanced Enzyme Technologies Ltd is India's largest enzyme manufacturer in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 3,693 Cr and reported net sales of 1,672 Cr and net profit of 265 Cr for Q1 2025. The company has a P/E ratio of 28.00 and a dividend yield of 1.55%.

Overview:<BR>Advanced Enzyme Technologies Ltd is the largest Indian enzyme company engaged in the manufacturing and sale of enzymes, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap.<BR><BR>History:<BR>The company was incorporated in 1989 as 'Advanced Biochemicals Private Limited' and later converted into a Public Company, changing its name to Advanced Biochemicals Limited in 1992. The most recent quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,672 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 265 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: INR 3,693 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 28.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 1.55%<BR>- Debt Equity: -0.39<BR>- Return on Equity: 9.23%<BR>- Price to Book: 2.59<BR><BR>Contact Details:<BR>Address: Sun Magnetica 5th Floor, Nr LIC Service Road Louiswadi Thane Maharashtra : 400604<BR>Tel: 91-22-41703200<BR>Email: info@advancedenzymes.com<BR>Website: http://www.advancedenzymes.com

Are Advanced Enzyme latest results good or bad?

Advanced Enzyme Technologies reported strong financial results for June 2025, with net sales up 20.31% year-on-year and record profits. However, a decline in cash reserves raises concerns about short-term liquidity, so while the results are generally positive, caution is advised.

Advanced Enzyme Technologies has reported a strong financial performance for the quarter ending June 2025, indicating positive results overall. The company achieved net sales of Rs 185.91 crore, which is a significant year-on-year growth of 20.31%. This marks the highest quarterly sales in the past five quarters, suggesting a robust sales trend.<BR><BR>Additionally, the operating profit (PBDIT) reached Rs 56.43 crore, and profit before tax (PBT) was reported at Rs 46.05 crore, both of which are the highest figures seen in the last five quarters. Profit after tax (PAT) also peaked at Rs 39.93 crore, leading to an earnings per share (EPS) of Rs 3.57. These results reflect a notable improvement in the company's financial health, with an overall score increasing from -11 to 10 over the last three months.<BR><BR>However, it's important to note that the company is facing challenges with its cash and cash equivalents, which have decreased to Rs 107.69 crore, the lowest level in the last six half-yearly periods. This decline indicates a potential concern regarding short-term liquidity.<BR><BR>In summary, while Advanced Enzyme Technologies has shown strong growth in sales and profits, the drop in cash reserves may pose challenges moving forward. Overall, the latest results can be considered good, but with caution regarding liquidity.

How has been the historical performance of Advanced Enzyme?

Advanced Enzyme has shown consistent growth in net sales, increasing from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25, but faced rising expenditures leading to a decline in operating profit and net profit. Total assets and liabilities both grew to 1,611.15 Cr by Mar'25, while cash flow from operations remained stable despite a net cash outflow of -19 Cr.

Answer:<BR>The historical performance of Advanced Enzyme shows a consistent growth in net sales and total operating income over the years, with net sales increasing from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25. The total operating income followed a similar trend, rising from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25. However, the total expenditure has also increased, reaching 442.47 Cr in Mar'25 from 237.67 Cr in Mar'19, which has impacted the operating profit, which decreased from 240.46 Cr in Mar'21 to 227.48 Cr in Mar'25. The profit before tax showed fluctuations, peaking at 210.13 Cr in Mar'21 and slightly declining to 187.36 Cr in Mar'25. The profit after tax also experienced a decline from 151.29 Cr in Mar'21 to 133.97 Cr in Mar'25. The earnings per share (EPS) decreased from 13.06 in Mar'21 to 11.72 in Mar'25, reflecting the overall profit trend. On the balance sheet, total assets grew from 971.18 Cr in Mar'20 to 1,611.15 Cr in Mar'25, while total liabilities increased from 971.18 Cr to 1,611.15 Cr in the same period. Cash flow from operating activities remained relatively stable, with a slight increase from 140 Cr in Mar'23 to 142 Cr in Mar'25, although the net cash outflow was recorded at -19 Cr in Mar'25.<BR><BR>Breakdown:<BR>Advanced Enzyme has demonstrated a robust growth trajectory in net sales, which rose from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25, indicating a strong demand for its products. The total operating income mirrored this growth, reaching 636.91 Cr in Mar'25. Despite this growth, total expenditure also increased significantly, leading to a decline in operating profit from 240.46 Cr in Mar'21 to 227.48 Cr in Mar'25. Profit before tax fluctuated, peaking at 210.13 Cr in Mar'21 before settling at 187.36 Cr in Mar'25, while profit after tax decreased from 151.29 Cr in Mar'21 to 133.97 Cr in Mar'25. The EPS followed a similar downward trend, dropping from 13.06 to 11.72 over the same period. On the balance sheet, total assets and liabilities both grew to 1,611.15 Cr by Mar'25, reflecting the company's expanding operations. Cash flow from operating activities remained stable, although the company faced a net cash outflow of -19 Cr in Mar'25, highlighting challenges in cash management despite operational profitability.

Should I buy, sell or hold Advanced Enzyme?

Is Advanced Enzyme technically bullish or bearish?

As of December 1, 2025, the technical trend for Advanced Enzyme has shifted to mildly bearish, driven by bearish MACD readings and Bollinger Bands, despite some mixed signals from daily moving averages and RSI.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven primarily by the weekly and monthly MACD readings, both indicating bearish momentum. The Bollinger Bands also reflect a mildly bearish outlook on both weekly and monthly time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the bearish signals from the KST and the overall trend change. The RSI presents a mixed picture with no signal on the weekly and bullish on the monthly, but the lack of a clear trend in Dow Theory and OBV further supports the bearish stance. Overall, the indicators suggest a weak bearish sentiment in the current market environment for Advanced Enzyme.

Which are the latest news on Advanced Enzyme?

Why is Advanced Enzyme falling/rising?

As of 04-Dec, Advanced Enzyme Technologies Ltd's stock price is rising to 314.50, driven by strong recent financial performance and increased investor interest. However, long-term declines and valuation concerns remain significant.

As of 04-Dec, Advanced Enzyme Technologies Ltd's stock price is rising, currently at 314.50, reflecting a change of 1.25 (0.4%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.61% today and has been on a consecutive gain for the last two days, accumulating a total return of 1.5% during this period. Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 67.68% compared to the 5-day average, indicating heightened interest in the stock.<BR><BR>Moreover, the company's recent financial performance has shown positive results, particularly in the quarter ending September 25, where operating cash flow reached its highest at Rs 142.50 Cr, and net sales grew by 26.30% to Rs 184.53 Cr. The high institutional holdings at 31.82% also suggest that knowledgeable investors are backing the stock, which can instill confidence among retail investors.<BR><BR>However, it is important to note that despite the recent rise, the stock has experienced significant declines over the longer term, with a year-to-date decrease of 9.37% and a 1-year decline of 15.80%. This long-term underperformance, coupled with a low return on equity and a high price-to-book value ratio, raises concerns about the stock's valuation and growth potential. Nonetheless, the immediate factors contributing to the current rise include positive short-term performance metrics and increased trading activity.